Latest other current liabilities for ANTX: $2.9M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), ANTX shows a other current liabilities of $2.9M. That compares with $4.9M in the prior-year period — down 40.4% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ANTX's other current liabilities is now $2.9M (was $4.9M) — a 40.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether AN2 Therapeutics is outperforming or lagging.
Tracking ANTX's other current liabilities over time shows whether AN2 Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $2.9M That compares with $4.9M in the prior-year period — down 40.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this other current liabilities page, Stockcircle has AN2 Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $2.9M) with ownership activity and broader fundamentals.